[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1964

Thorotrast-Induced Carcinoma of the Liver: A Case Report Including Results of Whole Body Counting

Author Affiliations

Surgical Resident, Stanford University, presently Chief Surgical Resident, Santa Clara County Hospital (Dr. Person).; Donner Laboratory of Medical Physics and Biophysics, University of California (Drs. Sargent and Isaac).

Arch Surg. 1964;88(3):503-510. doi:10.1001/archsurg.1964.01310210177030

I. Introduction  Thorotrast was first employed clinically in 1928 by Blühbaum, Frik, and Kalkbrenner.1 During the period from 1930 to 1950, it was used widely in Europe and to a lesser extent in the United States for visualization of cavity spaces, cerebral angiography, and visualization of the reticuloendothelial system. Thorotrast utilization has been curtailed in the last decade because of the immediate sequelae of induration at the site of injection, because of granuloma formation when injected interstitially, and particularly because of increasing evidence of the delayed sequelae of irradiation-induced malignant neoplasms.2,3Thorotrast is a colloidal solution of thorium dioxide (ThO2) of about 20% by weight in invert carbohydrate solution. Thorium dioxide (Thorotrast) has a particulate size of 3 to 10 mμ, and parent Th232 has a half-life of 1.39 × 1010 years.Tumors have occurred at the site of injection of Thorotrast when used for